Following the news from Europe
Provided by AGP
Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
The myasthenia gravis market size reached approximately USD 6 billion in 2025 across the 7MM and is growing at a robust CAGR of 9.1% during the forecast period. This remarkable growth is being underpinned by surging diagnosed prevalence, a rapidly evolving pipeline of targeted therapies, including Immunovant/Roivant Sciences’ IMVT-1402, Cartesian Therapeutics’ Descartes-08, Novartis’ FABHALTA, Alexion AstraZeneca Rare Disease’s Gefurulimab, RemeGen/Vor Bio’s Telitacicept, and others.
New York, USA, May 18, 2026 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight
The myasthenia gravis market size reached approximately USD 6 billion in 2025 across the 7MM and is growing at a robust CAGR of 9.1% during the forecast period. This remarkable growth is being underpinned by surging diagnosed prevalence, a rapidly evolving pipeline of targeted therapies, including Immunovant/Roivant Sciences’ IMVT-1402, Cartesian Therapeutics’ Descartes-08, Novartis’ FABHALTA, Alexion AstraZeneca Rare Disease’s Gefurulimab, RemeGen/Vor Bio’s Telitacicept, and others.
Ramandeep Singh, senior consultant of forecasting at DelveInsight, said that several emerging therapies are poised to redefine the autoimmune treatment landscape through differentiated mechanisms, improved safety, and enhanced patient convenience. Among these, IMVT-1402 stands out as a strategically significant FcRn inhibitor candidate with the potential to establish a new benchmark by combining strong efficacy with a favorable safety profile, factors considered essential for long-term success in autoimmune indications.
On the other hand, Iptacopan’s oral administration and broad applicability across complement-mediated disorders could help it secure a differentiated position in the gMG market, particularly among patients inadequately managed with existing therapies. Additionally, Singh emphasized that remibrutinib’s convenient oral dosing and targeted, steroid-sparing approach may strengthen its appeal if clinical outcomes remain favorable. Meanwhile, Descartes-08 is viewed as a potentially transformative therapy in autoimmune neurology, with the capability to address the growing demand for safer, more durable, and patient-centric treatment options.
Find out how common generalized myasthenia gravis is @ https://www.delveinsight.com/sample-request/myasthenia-gravis-market
Key Epidemiological Findings from the Myasthenia Gravis Report
DelveInsight's epidemiological analysis reveals a significant and growing patient burden across the 7MM:
- ~300,000 total diagnosed prevalent myasthenia gravis cases were recorded across the 7MM in 2025
- ~140,000 diagnosed prevalent cases of myasthenia gravis were reported in the United States alone in 2025.
- In the US, the anti-AChR Ab (+ve) category accounts for the highest number of generalized MG (gMG) cases at 76,500, followed by anti-MuSK Ab (+ve) with 4,500 cases, and the double seronegative group accounting for ~9,000 cases
- Gender disparities persist: In the US, females accounted for approximately 81,000 cases versus 54,000 cases in males in 2025
- By the MGFA severity classification in the US, mild generalized disease constitutes the largest share at ~43% of all diagnosed cases in 2025
- In Japan, MGFA Class II recorded the highest case count at 16,000, followed by Class I with 13,000 cases
- The rising prevalence is attributed to advancements in diagnostic techniques, an aging global population, environmental influences, hereditary risk factors, and increased disease awareness
Myasthenia Gravis Epidemiology Segmentation
The myasthenia gravis patient pool analysis section provides insights into the historical and current myasthenia gravis patient pool and forecasted trends for the leading markets. The myasthenia gravis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:
- Total Diagnosed Prevalent Cases of Myasthenia Gravis
- Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification
- Total Diagnosed Prevalent Cases of gMG
- Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis
- Diagnosed Prevalent Cases of gMG by Antibody Serology
Download the sample page to understand myasthenia gravis prevalence by country @ Myasthenia Gravis Epidemiology Forecast
Key Factors Driving the Myasthenia Gravis Market Growth
- Growing geriatric population leading to increase in MG market: The aging global population is contributing to the rise in MG cases, as the disease often manifests in older adults. Around 70K diagnosed prevalent cases of myasthenia gravis occurred in the age group 65 years and above in 7MM in 2025, due to increased autoimmune susceptibility and improved diagnostics, leading to greater detection and accumulation in older patients. This demographic shift is expanding the patient base and increasing the need for effective treatments.
- Improved diagnosis & awareness increasing myasthenia gravis patient pool, which further boosts market: Greater physician awareness, better antibody testing (AChR, MuSK, LRP4), and access to electrodiagnostic tools have increased detection rates. Historically underdiagnosed mild or ocular cases are now more frequently identified.
- Advancements in biologic myasthenia gravis therapies driving MG market growth: A range of targeted therapies has transformed the myasthenia gravis treatment market, including Neonatal Fc Receptor (FcRn) inhibitors like RYSTIGGO, VYVGART, VYVGART HYTRULO/VYVDURA, IMAAVY; complement inhibitors such as SOLIRIS and ULTOMIRIS, and the Complement C5 inhibitor ZILBRYSQ. These advances reflect a shift toward precision immunotherapy and improved patient outcomes.
- Shifting myasthenia gravis treatment paradigms propelling MG market growth: The focus of treatment is shifting from short-term symptom control to restoring long-term immune balance by targeting antibody production and B-cell activity. This evolving approach, seen across autoimmune diseases, is driving innovation in the myasthenia gravis clinical trial, with candidates like RNA CAR T-cell therapy (Descartes-08), dual complement inhibitors (pozelimab + cemdisiran), and BLyS/APRIL pathway blockers (telitacicept) reflecting this myasthenia gravis market trend.
- Robust myasthenia gravis clinical trial activity is expected to boost market growth: The myasthenia gravis treatment pipeline is robust and expanding, with numerous therapies in development across different stages. Key investigational drugs in clinical trials include IMVT-1402 (Immunovant/Roivant Sciences), Cladribine capsules (Merck KGaA), Remibrutinib (Novartis), Gefurulimab (Alexion AstraZeneca Rare Disease), Iptacopan (FABHALTA) (Novartis), Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), Descartes-08 (Cartesian Therapeutics), KYV-101 (Kyverna Therapeutics), Claseprubart (DNTH103) (Dianthus Therapeutics), NMD670 (NMDP-01) (NMD Pharma), IM-101 (ImmunAbs), and others.
Myasthenia Gravis Market Analysis
- The therapeutic landscape has evolved significantly with the introduction of targeted biologics that enable more precise intervention in underlying disease pathways.
- Regulatory-approved therapies such as IMAAVY, RYSTIGGO, ZILBRYSQ, VYVGART, and ULTOMIRIS highlight a transition toward complement inhibition and FcRn blockade, targeting core disease mechanisms rather than relying solely on broad immunosuppression.
- In a notable recent development, UCB's CHMP received a positive opinion in March 2026 for the pre-filled pen version of zilucoplan (ZILBRYSQ), further improving patient convenience and expanding its commercial footprint across Europe.
- The current myasthenia gravis market is largely led by argenx and UCB, supported by robust product portfolios and growing leadership in targeted immunotherapy.
- Looking ahead, the myasthenia gravis therapeutics market is expected to expand further with emerging candidates such as IMVT-1402, Descartes-08, and remibrutinib, each designed to address distinct immune pathways, including FcRn blockade, CAR-T cell therapy, and BTK inhibition.
- Currently, more than 10 therapies are in late-stage development (Phase III), while an additional five therapies are progressing through Phase II clinical trials. The anticipated launch of these emerging therapies is expected to significantly accelerate market growth.
Learn more about why FcRn inhibitors are disrupting the MG market @ Myasthenia Gravis Treatment Market
Myasthenia Gravis Clinical Trial Analysis
The myasthenia gravis pipeline is among the most active in rare neuromuscular disorders, with several transformative candidates in late-stage clinical development:
- Immunovant/Roivant Sciences’ IMVT-1402: Next-generation FcRn blocker targeting broader patient populations. As per the company’s 2025 report, top-line results from the IMVT-1402 study are anticipated to be reported in 2027, marking a key milestone in the clinical development timeline for this investigational therapy.
- Cartesian Therapeutics’ Descartes-08: A CAR-T cell therapy targeting CD19-positive B cells. In November 2025, Cartesian Therapeutics reported that enrollment is on track in the Phase III AURORA trial evaluating Descartes-08 in participants with myasthenia gravis.
- Novartis’ FABHALTA (Iptacopan): A complement factor B inhibitor in late-stage development, targeting the alternative complement pathway. The drug is marketed as FABHALTA and has already been approved for use in another indication. Novartis plans to submit Phase III data for gMG by 2027.
- Alexion AstraZeneca Rare Disease’s Gefurulimab: An anti-C5 albumin-binding humanized bispecific VHH antibody optimized for subcutaneous delivery. According to the latest pipeline updates, gefrulimab has entered the regulatory review phase, with its first major market submission already completed, marking it as a prospective new competitor in the generalized myasthenia gravis treatment landscape.
- RemeGen/Vor Bio’s Telitacicept: A novel fusion protein designed to neutralize key B-cell-stimulating factors in autoimmune diseases. It has already received regulatory approval in China for gMG, marking a significant milestone as the first therapeutic globally to target both BLyS and APRIL in this indication.
- Novartis’ Remibrutinib: A selective BTK inhibitor addressing upstream B-cell activation in gMG. Novartis’s recent report reported that regulatory submission is expected no earlier than 2028.
As per Singh, the 7MM Myasthenia Gravis market is poised for sustained growth during 2022–2036, driven by the launch of first-in-class therapies, improving diagnostic and testing capabilities, and increasing disease awareness. By 2036, Singh said, VYVGART HYTRULO/VYVDURA is projected to generate the highest revenue among all available therapies across the 7MM, reflecting strong physician uptake and growing preference for targeted treatment approaches. Meanwhile, Japan continues to emerge as a resilient and increasingly competitive market for myasthenia gravis therapies.
Discover more about upcoming myasthenia gravis drug launches @ Myasthenia Gravis Clinical Trials
| Myasthenia Gravis Market Report Metrics | Details |
| Study Period | 2022–2036 |
| Myasthenia Gravis Market Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Myasthenia Gravis Market CAGR | 9.1% |
| Myasthenia Gravis Market Size in 2025 | USD 6 Billion |
| Key Myasthenia Gravis Companies | Immunovant, Roivant Sciences, Merck KGaA, Novartis, Alexion AstraZeneca Rare Disease, Regeneron Pharmaceuticals, Cartesian Therapeutics, Kyverna Therapeutics, Dianthus Therapeutics, NMD Pharma, ImmunAbs, UCB, Johnson & Johnson, argenx, Amgen, and others |
| Key Myasthenia Gravis Therapies | IMVT-1402, Cladribine capsules, Remibrutinib, Gefurulimab, Iptacopan (FABHALTA), Pozelimab + Cemdisiran, Descartes-08, NMD670 (NMDP-01), IM-101, IMAAVY, RYSTIGGO, ZILBRYSQ, VYVGART, ULTOMIRIS, and others |
Scope of the Myasthenia Gravis Market Report
- Myasthenia Gravis Patient Population Forecast
- Myasthenia Gravis Therapeutics Market Size
- Myasthenia Gravis Pipeline Analysis
- Myasthenia Gravis Market Size and Trends
- Myasthenia Gravis Market Opportunity
- Myasthenia Gravis Market Unmet Needs
- KOL’s Views on Myasthenia Gravis
- Myasthenia Gravis Market Access and Reimbursement
To know more about which therapy class will dominate MG by 2036, visit @ Myasthenia Gravis Medication
Table of Contents
| 1 | Myasthenia Gravis Market Key Insights |
| 2 | Myasthenia Gravis Market Report Introduction |
| 3 | Myasthenia Gravis Market Overview at a Glance |
| 3.1 | Clinical Landscape Analysis (By Phase, RoA, and Molecule Type) |
| 3.2 | Market Share (%) Distribution of Myasthenia Gravis by Therapies in the 7MM in 2025 |
| 3.3 | Market Share (%) Distribution of Myasthenia Gravis by Therapies in the 7MM in 2036 |
| 4 | Executive Summary |
| 5 | Key Events |
| 6 | Background and Overview |
| 6.1 | Introduction |
| 6.2 | Types of Myasthenia Gravis |
| 6.3 | Clinical Manifestations |
| 6.4 | Etiology |
| 6.5 | Risk Factors |
| 6.6 | Symptoms |
| 6.7 | Pathophysiology |
| 6.8 | Biomarkers |
| 6.9 | Diagnosis |
| 6.10 | Treatment and Management |
| 6.11 | Diagnosis and Treatment Guidelines |
| 7 | Epidemiology and Market Methodology |
| 8 | Epidemiology and Patient Population |
| 8.1 | Key Findings |
| 8.2 | Assumptions and Rationale |
| 8.2.1 | Diagnosed Prevalent Cases of Myasthenia Gravis |
| 8.2.2 | Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification |
| 8.2.3 | Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis |
| 8.2.4 | Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis |
| 8.2.5 | Diagnosed Prevalent Cases of gMG by Antibody Serology |
| 8.3 | Total Diagnosed Prevalent Cases of Myasthenia Gravis in the 7MM |
| 8.4 | The United States |
| 8.4.1 | Total Diagnosed Prevalent Cases of Myasthenia Gravis in the US |
| 8.4.2 | Severity-specific Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Classification in the US |
| 8.4.3 | Total Diagnosed Prevalent Cases of gMG in the US |
| 8.4.4 | Gender-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US |
| 8.4.5 | Age-specific Diagnosed Prevalent Cases of Myasthenia Gravis in the US |
| 8.4.6 | Diagnosed Prevalent Cases of gMG by Antibody Serology in the US |
| 8.5 | EU4 and the UK |
| 8.6 | Japan |
| 9 | Myasthenia Gravis Patient Journey |
| 10 | Marketed Myasthenia Gravis Therapies |
| 10.1 | Competitive Landscape: Marketed Drugs |
| 10.2 | Rozanolixizumab-noli (RYSTIGGO): UCB |
| 10.2.1 | Product Description |
| 10.2.2 | Regulatory Milestones |
| 10.2.3 | Other Developmental Activities |
| 10.2.4 | Summary of Pivotal Trial |
| 10.2.5 | Ongoing Clinical Development Activity |
| 10.2.5.1 | Safety and Efficacy |
| 10.2.6 | Analyst Views |
| 10.3 | Zilucoplan (ZILBRYSQ): UCB |
| 10.4 | Nipocalimab-aahu (IMAAVY): Johnson & Johnson |
| 10.5 | Ravulizumab (ULTOMIRIS): Alexion AstraZeneca Rare Disease |
| 10.6 | Efgartigimod alfa-fcab (VYVGART): Argenx |
| 10.7 | Efgartigimod alfa and Hyaluronidase-qvfc (VYVGART HYTRULO/VYVDURA): Argenx |
| List to be continued in the final report… | |
| 11 | Emerging Myasthenia Gravis Therapies |
| 11.1 | Competitive Landscape: Emerging Drugs |
| 11.2 | IMVT-1402: Immunovant/Roivant Sciences |
| 11.2.1 | Drug Description |
| 11.2.2 | Other Developmental Activities |
| 11.2.3 | Clinical Development Activity |
| 11.2.4 | Safety and Efficacy |
| 11.2.5 | Analyst Views |
| 11.3 | Cladribine (MAVENCLAD): Merck KGaA |
| 11.4 | Remibrutinib: Novartis |
| 11.5 | Gefurulimab: Alexion AstraZeneca Rare Disease |
| 11.6 | Iptacopan (FABHALTA): Novartis |
| 11.7 | Pozelimab + Cemdisiran: Regeneron Pharmaceuticals |
| 11.8 | Descartes-08: Cartesian Therapeutics |
| 11.9 | KYV-101: Kyverna Therapeutics |
| 11.1 | Claseprubart (DNTH103): Dianthus Therapeutics |
| 11.11 | NMD670 (NMDP-01): NMD Pharma |
| 11.12 | IM-101: ImmunAbs |
| 11.13 | Cladribine (MAVENCLAD): Merck KGaA |
| List to be continued in the final report… | |
| 12 | Myasthenia Gravis Market – 7MM Market Analysis |
| 12.1 | Key Findings |
| 12.2 | Key Myasthenia Gravis Market Forecast Assumptions |
| 12.3 | Myasthenia Gravis Market Outlook |
| 12.4 | Attribute Analysis |
| 12.5 | Total Market Size of Myasthenia Gravis in the 7MM |
| 12.6 | Market Size of Myasthenia Gravis by RoA in the 7 MM |
| 12.7 | Market Size of Myasthenia Gravis by MoA in the 7 MM |
| 12.8 | Market Size of Myasthenia Gravis by Therapies in the 7MM |
| 12.9 | The United States Myasthenia Gravis Market Size |
| 12.9.1 | Total Market Size of Myasthenia Gravis in the US |
| 12.9.2 | Market Size of Myasthenia Gravis by RoA in the US |
| 12.9.3 | Market Size of Myasthenia Gravis by MoA in the US |
| 12.9.4 | Market Size of Myasthenia Gravis by Therapies in the US |
| 12.10 | EU4 and the UK Myasthenia Gravis Market Size |
| 12.11 | Japan Myasthenia Gravis Market Size |
| 13 | Key Opinion Leaders’ Views on Myasthenia Gravis |
| 13.1 | Expert/KOL Interview Highlights |
| 14 | Myasthenia Gravis Market Unmet Needs |
| 15 | Myasthenia Gravis Market SWOT Analysis |
| 16 | Myasthenia Gravis Market Access and Reimbursement |
| 16.1 | The United States |
| 16.2 | EU4 and the UK |
| 16.3 | Japan |
| 16.4 | Reimbursement Scenario in gMG |
| 17 | Acronyms and Abbreviations |
| 18 | Bibliography |
| 19 | Myasthenia Gravis Market Report Methodology |
Related Reports
FcRn Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key FcRn inhibitors companies, including Immunovant, Viridian Therapeutics, argenx, UCB, Johnson & Johnson, and others.
Complement Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key complement inhibitors companies, including AstraZeneca (Alexion Pharmaceuticals), F. Hoffmann-La Roche, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Kira Pharmaceuticals, Regeneron Pharmaceuticals, NovelMed Therapeutics, Sanofi, Amyndas Pharmaceuticals, Novartis, Apellis, Sobi, Astellas, and others.
Myasthenia Gravis Clinical Trial Analysis Pipeline
Myasthenia Gravis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including RemeGen, Takeda, Immunovant Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, Cabaletta Bio, Momenta Pharmaceuticals, Kyverna Therapeutics, Amgen, COUR Pharmaceutical Development Company, and others.
Generalized Myasthenia Gravis Market
Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gMG companies, including Novartis, Alexion AstraZeneca Rare Disease, Cabaletta Bio, UCB, Immunovant, Roivant Sciences, Cartesian Therapeutics, Merck KGaA, RemeGen, Regeneron Pharmaceuticals, and others.
Generalized Myasthenia Gravis Clinical Trial Analysis
Generalized Myasthenia Gravis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key gMG companies, including Novartis, Alexion AstraZeneca Rare Disease, Cabaletta Bio, UCB, Immunovant, Roivant Sciences, Cartesian Therapeutics, Merck KGaA, RemeGen, Regeneron Pharmaceuticals, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
